A vs SYRE
Agilent Technologies vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
A
Agilent Technologies
70
Buy
VS
SYRE
Spyre Therapeutics, Inc.
72
Buy
| Metric | A | SYRE |
|---|
| AI Score |
70
|
72
|
| Price |
$148.44
|
$103.56
|
| P/E Ratio |
29.77×
|
-53.14×
|
| ROE |
19.3%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
53.0%
|
0.0%
|
| Debt / Equity |
0.47×
|
0.00×
|
| Dividend Yield |
0.7%
|
0.0%
|
| RSI (14) |
72.2
|
54.6
|
| Beta |
1.229
|
3.026
|
| Expected Upside |
+0.4%
|
—
|
AI Committee View
Current Innellis committee reasoning for A versus SYRE.
SYRE leads by 2 points.
SYRE scores 72/100 (Buy) versus A at 70/100 (Buy).
A Committee View
80% agreement
5 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- RSI at 72 is in overbought territory — Technical
- Bollinger bandwidth of 16.1% signals elevated volatility — Risk
SYRE Committee View
100% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 79 -- overbought on the larger timeframe too — Technical